This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure criteria while receiving bosutinib in Part A may be able to receive olverembatinib in crossover follow-on study.
The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part 1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a confirmatory cohort where patients will be treated at the same doses assessed in Part 2
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (CAR T-cell) and T-cell redirecting therapies (such as T-cell engager bispecific antibody \[TCE BsAb\] therapy). The primary objective is to demonstrate that true annualized rate of serious bacterial infection (SBIs) is less than (\<) 1.0. This study includes two cohorts: 1. Loading Cohort: Participants with serum immunoglobulin G (IgG) \< 500 milligrams per deciliter (mg/dL) at Screening, with or without ongoing immunoglobulin replacement therapy (IgRT) during Screening, who must have received five doses of IgPro20 during the Initial Treatment Period. 2. Maintenance-only Cohort: Participants with serum IgG greater than or equal to (≥) 500 mg/dL and ongoing IgRT at Screening, who must have received one dose of IgPro20 during the Initial Treatment Period.
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with MDS. * Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with AML. * Part D will find out how much SEA-CD70 with azacitidine should be given to participants * Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML that has not been treated. * Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML. * Part G will find out how much SEA-CD70 with azacitidine and with venetoclax should be given to participants with AML. Also, to evaluate safety and tolerability of PF-08046040 in combination with azacitidine and venetoclax in participants with previously untreated AML who are unfit for standard induction chemotherapy.
Original English text from ClinicalTrials.gov
✓ Qualifies
Simplified criteria — AI translation
University of Alabama at Birmingham
Birmingham, United States
University of Alabama at Birmingham
Birmingham, United States
Dept. of Medicine, UAB ONeal Comprehensive Cancer Center
Birmingham, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, United States
IP Address: City of Hope Investigational Drug Services(IDS)
Duarte, United States
Ronald Reagan UCLA Medical Center
Los Angeles, United States
UCLA Hematology-Oncology Clinic
Los Angeles, United States
Colorado Blood Cancer Institute, Lab
Denver, United States
Colorado Blood Cancer Institute
Denver, United States
Presbyterian/St. Luke's Medical Center
Denver, United States
The University of Kansas Cancer Center ,Investigational Drug Services
Fairway, United States
The University of Kansas Clinical Research Center
Fairway, United States
The University of Kansas Hospital
Kansas City, United States
University of Kansas Hospital Cambridge North Tower A
Kansas City, United States
University of Kansas Medical center Medical office building
Kansas City, United States
University of Kansas Medical Center Research Institute
Kansas City, United States
The University of Kansas Cancer Center - Overland Park
Overland Park, United States
The University of Kansas Cancer Center - Indian Creek Campus
Overland Park, United States
The University of Kansas Cancer Center
Westwood, United States
Norton Hospitals, Inc
Louisville, United States
Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD
Louisville, United States
Norton Cancer Institute, St. Matthews Campus
Louisville, United States
Norton Women & Children's Hospital
Louisville, United States
Massachusetts General Hospital
Boston, United States
Beth Israel Deaconess Medical Center
Boston, United States
Dana Farber/Mass General Brigham Cancer Care, Inc
Boston, United States
Karmanos Cancer Institute
Detroit, United States
Karmanos Cancer Institute Weisberg Cancer Treatment Center
Farmington Hills, United States
The University of Kansas Cancer Center - Medical Oncology Clinic
Kansas City, United States
The University of Kansas Cancer Center -North
Kansas City, United States
The University of Kansas Cancer Center - Lee's Summit
Lee's Summit, United States
Columbia University Irving Medical Center
New York, United States
CUIMC Research Pharmacy
New York, United States
The New York and Presbyterian Hospital
New York, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
Cleveland Clinic
Cleveland, United States
The Ohio State University Wexner Medical Center/James Cancer Hospital
Columbus, United States
Hollings Cancer Center
Charleston, United States
Medical University of South Carolina- Ashley River Tower
Charleston, United States
Medical University of South Carolina- Investigational Drug Services
Charleston, United States
Medical University of South Carolina- University Hospital
Charleston, United States
Baylor Research Institute
Dallas, United States
Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy
Dallas, United States
Baylor University Medical Center
Dallas, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Swedish Cancer Institute
Seattle, United States
Swedish Medical Center
Seattle, United States
National Cancer Center Hospital East
Kashiwa, Japan
Nippon Medical School Hospital
Bunkyo-ku, Japan
Yamagata University Hospital
Yamagata, Japan
Pharmacy - UMC Utrecht t.a.v. Apotheek KGO
Utrecht, Netherlands
University Medical Center (UMC) Utrecht
Utrecht, Netherlands
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.
We use Google Analytics to understand how you use our tools and to improve them. We don't collect health data and we don't show ads. You can decline - the site will work exactly the same. Privacy policy